Kepivance Amgen Inc. - Treatment for Severe Oral Mucositis in Cancer Patients
Kepivance is a recombinant human keratinocyte growth factor
indicated to decrease the incidence and duration of severe oral
mucositis (mouth sores) in patients with hematologic (blood)
cancers undergoing high-dose chemotherapy, with or without
radiation, followed by a bone marrow transplant.
Posted: December 2004
Kepivance (palifermin) FDA Approval History